[HTML][HTML] Effectiveness of BNT162b2 vaccine against omicron variant in South Africa

S Collie, J Champion, H Moultrie… - New England Journal …, 2022 - Mass Medical Soc
S Collie, J Champion, H Moultrie, LG Bekker, G Gray
New England Journal of Medicine, 2022Mass Medical Soc
Preliminary Data on Vaccine Protection against Omicron Using a test-negative study design
focused on the period of dominance of the B. 1.1. 529 (omicron) variant in South Africa,
investigators found that two doses of the BNT162b2 vaccine had an efficacy of 50 to 70%
against hospitalization caused by omicron in Gauteng province.
Preliminary Data on Vaccine Protection against Omicron
Using a test-negative study design focused on the period of dominance of the B.1.1.529 (omicron) variant in South Africa, investigators found that two doses of the BNT162b2 vaccine had an efficacy of 50 to 70% against hospitalization caused by omicron in Gauteng province.
The New England Journal Of Medicine